PEG MGF

Description

Overview of PEG-MGF

PEG-MGF refers to PEGylated variants of peptides derived from the IGF-1Ec splice variant of insulin-like growth factor 1 used in research settings. It is produced by covalently attaching polyethylene glycol (PEG) chains to the peptide backbone. This is a widely employed research method for improving molecular stability and extending persistence in controlled systems. 

PEGylation is often associated with reduced proteolytic degradation and altered clearance, depending on experimental conditions. However, PEG-MGF does not have a standardized monograph. Thus, specifications may vary depending on synthesis conditions, PEG chain length, and conjugation site distribution.

Chemical and Molecular Properties 

PubChem CID	No unique entry in PubChem due to its heterogeneous structure
Molecular Weight	Variable (~2.8 kDa + PEG mass)
Synonyms	PEG-MGF PEG-IGF-1Ec
IUPAC	Not assigned for complex pegylated biologics
CAS	No universally recognized CAS registry entry
Labeling	Research Use Only (RUO), not for human or animal consumption.
Chemical Structure Depiction
Purity	≥95%
Classification	Research Use Only (RUO)
Storage Temperature	Typically −20 °C (lyophilized)
Solubility	Aqueous solubility is generally enhanced by PEGylation, but actual solubility depends on PEG molecular weight, conjugation ratio, and formulation conditions.
Safety	Use gloves, a lab coat, and eye protection; avoid inhalation, ingestion, and contact. Handle in a well-ventilated area or fume hood if aerosolization is possible. Treat it as a potentially bioactive experimental compound with unknown human and animal toxicity.

Proposed Working Mechanism of PEG-MGF

Current research discussions describe PEG-MGF mainly through molecular signaling models. However, mechanistic characterization remains limited compared to observational findings in experimental models. Research has explored interactions with IGF-1 receptor-related signaling, cellular communication pathways, and the effects of PEGylation on peptide stability in experimental systems.

PEGylation is thought to reduce enzymatic degradation. This may extend peptide persistence in laboratory settings. The peptide sequence is also examined for possible interactions with IGF-related signaling networks. Preclinical studies have examined satellite cell-related signaling pathways in experimental models.

Researchers have explored potential associations with downstream signaling pathways such as PI3K/Akt in preclinical models. PEG conjugation may also influence diffusion, distribution, and clearance behavior during experimental observation.

Why Choose Purerawz for PEG-MGF?

Buy PEG-MGF for laboratory research use from our online shop. At Purerawz, we provide reference materials intended for laboratory research use. Each research compound comes with a Certificate of Analysis for verification of purity and concentration.

Note:

PEG-MGF is an investigational compound. It is not established as safe or effective for any therapeutic use.

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human use

Reference Links

• Braun, A. C., Gutmann, M., Mueller, T. D., Lühmann, T., & Meinel, L. (2018). Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate. Journal of Controlled Release: Official Journal of the Controlled Release Society, 279, 17–28. https://doi.org/10.1016/j.jconrel.2018.04.009 
• Kletzl, H., Guenther, A., Höflich, A., Höflich, C., Frystyk, J., Staack, R. F., Schick, E., Wandel, C., Bleich, N., & Metzger, F. (2017). First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. Growth Hormone & IGF Research: Official Journal of the Growth Hormone Research Society and the International IGF Research Society, 33, 9–16. https://doi.org/10.1016/j.ghir.2017.01.001 
• Peña, J. R., Pinney, J. R., Ayala, P., Desai, T. A., & Goldspink, P. H. (2015). Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction. Biomaterials, 46, 26–34. https://doi.org/10.1016/j.biomaterials.2014.12.050